ClinicalTrials.gg
CompletedNCT04704219KEYNOTE-B61Updated Nov 3, 2026Results posted

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

A Phase 2 interventional study of Pembrolizumab and Lenvatinib in Renal Cell Carcinoma, sponsored by Merck Sharp & Dohme LLC. Completed at 56 sites in 14 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Updated Nov 3, 2026Posted results revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing pembrolizumab in Carcinoma, Renal Cell — 17 open to participants now, 23 under way, 4 of them phase 3. pembrolizumab · Carcinoma, Renal Cell.

Enrollment
10th of 48
160 · median 41
Started
2021
with 3 others
Phase 2
30 of 48
12 open now
Registered
21st of 48
by date
Lead sponsor
7 of 48
Merck Sharp & Dohme LLC

Among the 48 studies testing pembrolizumab in Carcinoma, Renal Cell, this one is the 10th largest by enrollment, is one of 4 that started in 2021, is one of 30 in phase 2, and was the 21st registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

17 of the 48 studies testing pembrolizumab in Carcinoma, Renal Cell are open now, in 8 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing pembrolizumab in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

This study is being performed as a single-arm open-label study in order to rapidly provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with previously untreated advanced/metastatic non-clear cell renal cell carcinoma.

03

Conditions studied

  • Renal Cell Carcinoma

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Death-Ligand 1 (PDL1, PD-L1)
  • Pembrolizumab
  • Lenvatinib
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have a confirmed diagnosis of nccRCC.
  2. Has locally advanced/ disease (ie, Stage IV per the American Joint Committee on Cancer).
  3. Has received no prior systemic therapy for advanced nccRCC. Note: Prior /adjuvant therapy for nccRCC is acceptable if completed >12 months prior to allocation.
  4. Male participants agree to use approved during the treatment period for at least 7 days after the last dose of study medication, or refrain from heterosexual intercourse during this period.
  5. Female participants are not pregnant or breastfeeding, and are not a woman of (WOCBP), OR are a WOCBP that agrees to use contraception during the treatment period and for at least 120 days post pembrolizumab, or 30 days post lenvatinib, whichever occurs last.
  6. Has per 1.1 as assessed by BICR. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  7. Has submitted an sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue.
  8. Has Performance Status (KPS) ≥70% as assessed within 10 days prior to the start of study intervention.
  9. Has adequately controlled blood pressure with or without antihypertensive medications
  10. Have adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Has collecting duct histology.
  2. A who has a positive urine pregnancy test within 24 hours before the first dose of study intervention.
  3. Has a below the institutional (or local laboratory) normal range.
  4. Has radiographic encasement or invasion of a major blood vessel, or of intratumoral cavitation.
  5. Has cardiovascular disease within 12 months from first dose of study intervention.
  6. Has gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib.
  7. Has active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.
  8. Has had major surgery within 3 weeks prior to first dose of study intervention.
  9. Has received prior therapy with an anti-programmed cell-death 1 (), anti-programmed cell-death ligand 1 (PD-L1), or anti-programmed cell-death ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137).
  10. Has received prior systemic anticancer therapy including agents within 4 weeks prior to allocation.
  11. Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require , and not have had radiation pneumonitis. A 1-week is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease.
  12. Has received a live or attenuated vaccine within 30 days before the first dose of study intervention.
  13. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.
  14. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior the first dose of study intervention.
  15. Has a known additional that is progressing or has required active treatment within the past 3 years.

    Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.

  16. Has known active and/or carcinomatous meningitis.
  17. Has severe (≥Grade 3) to pembrolizumab, lenvatinib and/or any of their .
  18. Has an active disease that has required systemic treatment in past 2 years
  19. Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  20. Has an active infection requiring systemic therapy.
  21. Has a known history of (HIV) infection. No HIV testing is required unless mandated by local health authority.
  22. Has a known history of (defined as HBsAg reactive) or known active virus.
  23. Has a known history of active tuberculosis (TB; Bacillus tuberculosis).
  24. Has had an allogenic tissue/solid organ transplant.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Lenvatinib

    Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation PLUS Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.

    Biological: Pembrolizumab · Drug: Lenvatinib

Interventions

  • BiologicalPembrolizumab

    Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation.

    Also known as: KEYTRUDA®, MK-3475

  • Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.

    Also known as: LENVIMA®, Kisplyx, MK-7902, E7080

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who had a best overall response of either Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions as assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experienced a CR or PR as assessed per RECIST 1.1 by blinded independent central review (BICR) is presented.

    Time frame: Up to approximately 47 months

Secondary outcomes

  1. Duration of Response (DOR)

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. Duration of response per RECIST 1.1 by Blinded Independent Central Review (BICR) is presented.

    Time frame: Up to approximately 47 months

  2. Progression Free Survival (PFS)

    PFS was defined as the time from date of study treatment to the first documented progressive disease (PD) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The percentage of participants who experienced PFS per RECIST 1.1 by Blinded Independent Central Review (BICR) is presented.

    Time frame: Up to approximately 47 months

  3. Overall Survival (OS)

    OS was defined as the time from the date of study treatment to the date of death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. The OS for all participants is presented.

    Time frame: Up to approximately 47 months

  4. Clinical Benefit Rate (CBR)

    CBR is defined as the percentage of participants who have achieved Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm\]) of ≥6 months per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR).

    Time frame: Up to approximately 47 months

  5. Disease Control Rate (DCR)

    DCR was defined per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm\]). The appearance of one or more new lesions is also considered PD\]). Disease Control rate per RECIST 1.1 by Blinded Independent Central Review (BICR) is presented.

    Time frame: Up to approximately 47 months

  6. Number of Participants With One or More Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one or more AE is presented.

    Time frame: Up to approximately 55 months

  7. Number of Participants Who Discontinued From Study Treatment Due to an AE

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one or more AE is presented.

    Time frame: Up to approximately 55 months

07

Results

Posted Dec 3, 2025

Participant flow

This study was conducted at 47 centers in 14 countries.

Participant flow — Overall Study
MilestonePembrolizumab + Lenvatinib
Started160
Treated158
Second course treatment8
Completed0
Not completed160
Withdrew: Screen failure1
Withdrew: Withdrawal by subject1
Withdrew: Death89
Withdrew: Sponsor decision67
Withdrew: Site terminated by sponsor2

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants who had a best overall response of either Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions as assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experienced a CR or PR as assessed per RECIST 1.1 by blinded independent central review (BICR) is presented.

Time frame:
Up to approximately 47 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsPembrolizumab + Lenvatinib
Objective Response Rate (ORR)50.6 (42.6 to 58.7)
SecondaryDuration of Response (DOR)

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. Duration of response per RECIST 1.1 by Blinded Independent Central Review (BICR) is presented.

Time frame:
Up to approximately 47 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsPembrolizumab + Lenvatinib
Duration of Response (DOR)23.5 (16.5 to 29.5)
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from date of study treatment to the first documented progressive disease (PD) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The percentage of participants who experienced PFS per RECIST 1.1 by Blinded Independent Central Review (BICR) is presented.

Time frame:
Up to approximately 47 months
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsPembrolizumab + Lenvatinib
Progression Free Survival (PFS)17.9 (15.0 to 21.1)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of study treatment to the date of death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. The OS for all participants is presented.

Time frame:
Up to approximately 47 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab + Lenvatinib
Overall Survival (OS)41.5 (32.8 to NA)
SecondaryClinical Benefit Rate (CBR)

CBR is defined as the percentage of participants who have achieved Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm\]) of ≥6 months per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR).

Time frame:
Up to approximately 47 months
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR)
Percentage of participantsPembrolizumab + Lenvatinib
Clinical Benefit Rate (CBR)71.5 (63.8 to 78.4)
SecondaryDisease Control Rate (DCR)

DCR was defined per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm\]). The appearance of one or more new lesions is also considered PD\]). Disease Control rate per RECIST 1.1 by Blinded Independent Central Review (BICR) is presented.

Time frame:
Up to approximately 47 months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR)
Percentage of ParticipantsPembrolizumab + Lenvatinib
Disease Control Rate (DCR)82.3 (75.4 to 87.9)
SecondaryNumber of Participants With One or More Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one or more AE is presented.

Time frame:
Up to approximately 55 months
Reported as:
Number · Number of participants
Number of Participants With One or More Adverse Events (AEs)
Number of participantsPembrolizumab + Lenvatinib
Number of Participants With One or More Adverse Events (AEs)157
SecondaryNumber of Participants Who Discontinued From Study Treatment Due to an AE

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one or more AE is presented.

Time frame:
Up to approximately 55 months
Reported as:
Number · Number of participants
Number of Participants Who Discontinued From Study Treatment Due to an AE
Number of participantsPembrolizumab + Lenvatinib
Number of Participants Who Discontinued From Study Treatment Due to an AE49

Adverse events

Collected over Up to approximately 55 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + Lenvatinib First Course88/160 (55%)78/158 (49.4%)155/158 (98.1%)
Pembrolizumab + Lenvatinib Second Course2/8 (25%)2/8 (25%)5/8 (62.5%)
Most frequent serious events
Showing 10 of 102
Most frequent serious events
EventPembrolizumab + Lenvatinib First CoursePembrolizumab + Lenvatinib Second Course
ColitisGastrointestinal disorders0/1581/8
Incarcerated herniaGeneral disorders0/1581/8
Acute kidney injuryRenal and urinary disorders6/1580/8
AnaemiaBlood and lymphatic system disorders4/1580/8
Atrial fibrillationCardiac disorders4/1580/8
DiarrhoeaGastrointestinal disorders4/1580/8
AppendicitisInfections and infestations4/1580/8
Urinary tract infectionInfections and infestations4/1580/8
HyponatraemiaMetabolism and nutrition disorders3/1580/8
Cerebrovascular accidentNervous system disorders3/1580/8
Most frequent other events
Showing 10 of 71
Most frequent other events
EventPembrolizumab + Lenvatinib First CoursePembrolizumab + Lenvatinib Second Course
HypertensionVascular disorders93/1580/8
DiarrhoeaGastrointestinal disorders88/1581/8
HypothyroidismEndocrine disorders71/1581/8
FatigueGeneral disorders59/1581/8
ProteinuriaRenal and urinary disorders59/1581/8
Decreased appetiteMetabolism and nutrition disorders54/1580/8
NauseaGastrointestinal disorders52/1580/8
ArthralgiaMusculoskeletal and connective tissue disorders51/1580/8
DysphoniaRespiratory, thoracic and mediastinal disorders51/1580/8
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders50/1581/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pembrolizumab + Lenvatinib
<=18 years0
Between 18 and 65 years100
>=65 years60
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + Lenvatinib
Female48
Male112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + Lenvatinib
Hispanic or Latino0
Not Hispanic or Latino144
Unknown or Not Reported16
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + Lenvatinib
American Indian or Alaska Native0
Asian13
Native Hawaiian or Other Pacific Islander0
Black or African American5
White137
More than one race0
Unknown or Not Reported5
08

Study locations

56 sites
  • Georgetown University Medical Center ( Site 0001)
    Washington D.C., District of Columbia 20007, United States
  • St. Vincent Frontier Cancer Center ( Site 0004)
    Billings, Montana 59102, United States
  • Comprehensive Cancer Centers of Nevada ( Site 0010)
    Las Vegas, Nevada 89169, United States
  • Memorial Sloan Kettering Cancer Center ( Site 0015)
    New York, New York 10065, United States
  • Fox Chase Cancer Center ( Site 0011)
    Philadelphia, Pennsylvania 19111, United States
  • Vanderbilt University Medical Center ( Site 0008)
    Nashville, Tennessee 37232, United States
  • Seattle Cancer Care Alliance ( Site 0014)
    Seattle, Washington 98109, United States
  • MEDICAL COLLEGE OF WISCONSIN ( Site 0006)
    Milwaukee, Wisconsin 53226, United States
  • Macquarie University-MQ Health Clinical Trials Unit ( Site 0405)
    Macquarie Park, New South Wales 2109, Australia
  • Calvary Mater Newcastle ( Site 0403)
    Waratah, New South Wales 2298, Australia
  • Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si
    Brisbane, Queensland 4029, Australia
  • Ashford Cancer Centre Research ( Site 0404)
    Kurralta Park, South Australia 5037, Australia
  • Monash Health ( Site 0400)
    Clayton, Victoria 3168, Australia
  • Fiona Stanley Hospital ( Site 0402)
    Murdoch, Western Australia 6150, Australia
  • BC Cancer Vancouver-Clinical Trials Unit ( Site 1500)
    Vancouver, British Columbia V5Z 4E6, Canada
  • Sunnybrook Health Sciences Centre ( Site 1501)
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Centre ( Site 1504)
    Toronto, Ontario M5G 2M9, Canada
  • CHU de Quebec - Université Laval - Hotel Dieu de Quebec ( Site 1502)
    Québec, Quebec G1R 3S1, Canada
  • Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1007)
    Strasbourg, Alsace 67200, France
  • Centre François Baclesse ( Site 1000)
    Caen, Calvados 14076, France
  • Centre de Cancérologie du Grand Montpellier ( Site 1005)
    Montpellier, Languedoc-Roussillon 34070, France
  • centre hospitalier lyon sud ( Site 1003)
    Pierre-Bénite, Rhone 69310, France
  • Gustave Roussy ( Site 1002)
    Villejuif, Val-de-Marne 94800, France
  • Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Okta-Klinikai Onkológiai és Sugárterápiás C
    Miskolc, Borsod-Abauj Zemplen county 3526, Hungary
  • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 0303)
    Szolnok, Jász-Nagykun-Szolnok 5000, Hungary
  • Országos Onkológiai Intézet-Urogenital Tumors Department and Clinical Pharmacology ( Site 0304)
    Budapest, Pest County 1122, Hungary
  • Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 0300)
    Debrecen, 4032, Hungary
  • Tallaght University Hospital ( Site 1600)
    Dublin, D24 NR0A, Ireland
  • Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 0901)
    Rome, Lazio 00168, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0903)
    Milan, Lombardy 20133, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma-Oncology Unit ( Site 0902)
    Verona, Veneto 37134, Italy
  • Azienda Ospedaliera Santa Maria Terni-SC Oncologia ( Site 0900)
    Terni, 05100, Italy
  • Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu M-chemotherapy department ( Site 0800)
    Poznan, Greater Poland Voivodeship 60-569, Poland
  • Luxmed Onkologia sp. z o. o. ( Site 0802)
    Warsaw, Masovian Voivodeship 01-748, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
    Warsaw, Masovian Voivodeship 02-781, Poland
  • Russian Scientific Center of Radiology-Russian Scientific Center of Radiology ( Site 0602)
    Moscow, Moscow 117485, Russia
  • Volga District Medical Center-Urology Department ( Site 0604)
    Nizhny Novgorod, Nizhny Novgorod Oblast 603074, Russia
  • Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 0605)
    Nizhny Novgorod, Nizhny Novgorod Oblast 603081, Russia
  • SHBI Leningrad Regional Clinical Oncology Dispensary-Clinical Trials Department ( Site 0607)
    Saint Petersburg, 188663, Russia
  • Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1302)
    Seoul, 03722, South Korea
  • Asan Medical Center-Department of Oncology ( Site 1300)
    Seoul, 05505, South Korea
  • Samsung Medical Center ( Site 1301)
    Seoul, 06351, South Korea
  • Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 0200)
    Madrid, Madrid, Comunidad de 28034, Spain
  • Fundación Instituto Valenciano de Oncología-Oncologico ( Site 0202)
    Valencia, Valenciana, Comunitat 46009, Spain
  • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0201)
    Barcelona, 08035, Spain
  • Istanbul Universitesi Cerrahpasa ( Site 1104)
    Istanbul- Fatih, Istanbul 34098, Turkey (Türkiye)
  • Ege University Medicine of Faculty ( Site 1102)
    Bornova, İzmir 35100, Turkey (Türkiye)
  • Ankara University Hospital Cebeci ( Site 1105)
    Ankara, 06100, Turkey (Türkiye)
  • Hacettepe Universitesi-oncology hospital ( Site 1101)
    Ankara, 06230, Turkey (Türkiye)
  • Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 1103)
    Istanbul, 34722, Turkey (Türkiye)
  • Cherkasy Regional Oncology Dispensary ( Site 0504)
    Cherkassy, Cherkasy Oblast 18009, Ukraine
  • Chernihiv Medical Center of Modern Oncology ( Site 0509)
    Chernihiv, Chernihiv Oblast 14029, Ukraine
  • Dnepropetrovsk Regional Clinical Hospital Mechnikov-Department of urology ( Site 0508)
    Dnipro, Dnipropetrovsk Oblast 49005, Ukraine
  • CNPE "Regional Center of Oncology"-oncourology department ( Site 0502)
    Kharkiv, Kharkiv Oblast 61070, Ukraine
  • Cambridge University Hospital ( Site 1200)
    Cambridge, England CB2 0QQ, United Kingdom
  • The Christie ( Site 1205)
    Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, Tomczak P, Barthelemy P, Lee JL, Stus V, Ferguson T, Wiechno P, Gokmen E, Lacombe L, Gedye C, Perini RF, Sharma M, Peng X, Lee CH. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2023 Aug;24(8):881-891. doi: 10.1016/S1470-2045(23)00276-0. Epub 2023 Jul 11. PubMed 37451291 ↗
  • Voss MH, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, Tomczak P, Barthelemy P, Lee JL, Nalbandian T, Stus V, Ferguson T, Wiechno P, Gokmen E, Lacombe L, Gedye C, Cornell J, Sharma M, Burgents JE, Albiges L. First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial. Eur Urol. 2025 Dec;88(6):614-624. doi: 10.1016/j.eururo.2025.05.019. Epub 2025 Jul 24. PubMed 40707309 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jan 2025, 47 months.

Results were first posted in Dec 2025, 10 months after primary completion.

Of 47 industry-sponsored phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 47 months is above that.

Counting every sponsor, half of 231 studies reached it within 59 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2021
First posted
Jan 11, 2021
StartActual
Feb 23, 2021
Primary completionActual
Jan 27, 2025
CompletionActual
Oct 21, 2025
Results first posted
Dec 3, 2025
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Nov 3, 2026
Secondary outcomes
2 time frame changed
What changed in the outcomes
  • Time frameNumber of Participants With One or More Adverse Events (AEs)Up to approximately 56 months → Up to approximately 55 months
  • Time frameNumber of Participants Who Discontinued From Study Treatment Due to an AEUp to approximately 56 months → Up to approximately 55 months
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Posted results revised
    Secondary outcomes 2 time frame changed
    What changed in the outcomes
    • Time frameNumber of Participants With One or More Adverse Events (AEs)Up to approximately 56 months → Up to approximately 55 months
    • Time frameNumber of Participants Who Discontinued From Study Treatment Due to an AEUp to approximately 56 months → Up to approximately 55 months
    + 4 other changes: identifiers, verification date, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04704219
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Jan 11, 2021
Start date
Feb 23, 2021
Primary completion
Jan 27, 2025
Completion
Oct 21, 2025
Results posted
Dec 3, 2025
Last update
Nov 3, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Lenvatinib

Start the discussion